Epidarex Capital IV
◆ Fund Size
$145M
◆ Check Size
◆ Location
United Kingdom
◆ Portfolio
15 companies
◆ Activity
Statusactively investing
◆ Links
◆ Share this fund
◆ Investment Thesis
Focus on breakthrough academic and translational research for the creation of therapeutics and medical device companies, targeting significant unmet medical needs.
◆ About Epidarex Capital
Epidarex Capital is a transatlantic venture capital firm focused on building early-stage life science and health technology companies addressing major unmet needs in oncology, cardiometabolic, autoimmune, and neurological conditions. The firm leads early-stage financings, including Series A rounds, to bridge the equity funding gap for spinouts from UK and US research hubs, partnering with top scientists and entrepreneurs to build leadership teams and progress through key milestones. Epidarex Capital IV, LP has secured over $145 million in commitments and plans to invest in up to 15 companies.
◆ Sectors
◆ Stages
◆ Geography Focus
◆ Team
| Name | Title | Role | Links |
|---|---|---|---|
| Christine Hockley | Managing Director and Co-Head of Funds | Senior | |
| Elizabeth Roper, PhD | Managing Partner | Senior | in |
| Sinclair Dunlop | Managing Partner | Senior | in |
| A. Sinclair Dunlop | Managing Partner | — | in |
| Alicia MacLeod | Executive Assistant | — | in |
| Andrew Prince | Staff Accountant | — | |
| Anthony Voveris | Chief Financial Officer | — | in |
| Bridget Harris | Director of Operations | — | in |
| Clare Gaffney | Operations and Executive Assistant | — | |
| Elizabeth Roper Ph.D. | Managing Partner | — | in |
| Henning Steinhagen Ph.D. | Venture Partner | — | in |
| Kyparissia Sirinakis | Founding Partner | — | in |
| Lori Krim Gough Ph.D. | Partner | — | |
| Mary Canning Ph.D. | Partner | — | in |
| Matthew Miessau | Principal | — | in |
| Matthew Wright | Managing Partner | senior | |
| Melissa Lezameta Ph.D. | Senior Associate | — | in |
| Nigel Pitchford | Partner | senior | |
| Peter Finan Ph.D. | Managing Partner | — | in |
| Sara McGeachy | Investor Relations Analyst | — | |
| Timothy O'Shannessy | Partner | senior | |
| Victor Pong Ph.D. | Associate | — |
◆ Notable Investments
◆ Traits
Leads rounds
Co-invests
◆ FAQ
What does Epidarex Capital IV invest in?
Epidarex Capital IV invests in Biotech, Medtech and Drug Discovery at the seed stage.
Which geographies does Epidarex Capital IV focus on?
Epidarex Capital IV focuses on United Kingdom and United States, and is headquartered in United Kingdom.
What is Epidarex Capital IV's typical check size?
Epidarex Capital IV typically writes checks of $1M to $10M.